- Home
- ARTW vs CERO Comparison
ARTW vs CERO Comparison
Compare ARTW & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTW
- CERO
- Stock Information
- Founded
- ARTW 1956
- CERO 2017
- Country
- ARTW United States
- CERO United States
- Employees
- ARTW N/A
- CERO N/A
- Industry
- ARTW Industrial Machinery/Components
- CERO
- Sector
- ARTW Industrials
- CERO
- Exchange
- ARTW Nasdaq
- CERO Nasdaq
- Market Cap
- ARTW 9.3M
- CERO 3.5M
- IPO Year
- ARTW N/A
- CERO N/A
- Fundamental
- Price
- ARTW $2.04
- CERO $8.90
- Analyst Decision
- ARTW
- CERO Strong Buy
- Analyst Count
- ARTW 0
- CERO 2
- Target Price
- ARTW N/A
- CERO $45.00
- AVG Volume (30 Days)
- ARTW 36.8K
- CERO 3.3M
- Earning Date
- ARTW 07-10-2025
- CERO 08-13-2025
- Dividend Yield
- ARTW N/A
- CERO N/A
- EPS Growth
- ARTW N/A
- CERO N/A
- EPS
- ARTW 0.14
- CERO N/A
- Revenue
- ARTW $23,916,932.00
- CERO N/A
- Revenue This Year
- ARTW N/A
- CERO N/A
- Revenue Next Year
- ARTW N/A
- CERO N/A
- P/E Ratio
- ARTW $43.68
- CERO N/A
- Revenue Growth
- ARTW N/A
- CERO N/A
- 52 Week Low
- ARTW $1.40
- CERO $6.71
- 52 Week High
- ARTW $4.15
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ARTW 50.36
- CERO 46.23
- Support Level
- ARTW $1.88
- CERO $8.50
- Resistance Level
- ARTW $2.44
- CERO $9.73
- Average True Range (ATR)
- ARTW 0.15
- CERO 1.20
- MACD
- ARTW -0.00
- CERO -0.01
- Stochastic Oscillator
- ARTW 37.50
- CERO 14.54
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.